Stand Up To Cancer - standuptocancer.orgThis is where the end of cancer begins
   Please leave this field empty

Neo-antigen TCR Degeneracy Convergence Team

Share this:
Email

Like this page on Facebook

 

Computational Deconstruction of Neoantigen-TCR Degeneracy for Cancer

Team Leaders

  • Benjamin Greenbaum, PhD

    Team Leader
    Assistant Professor in Department of Genetics & Genomic Sciences, Medicine, Oncological Sciences, and Pathology at the Ichan School of Medicine
    + Full Bio
  • Vinod Balachandran, MD

    Co-Leader
    Assistant Attending Surgeon of Hepatopancreatobiliary Surgery, and a Member of the Parker Institute for Cancer Immunotherapy and the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center (MSKCC)
    + Full Bio

About This Team’s Research

The team will build on the work started under a Convergence 1.0 grant but further explore the underpinnings that constitute pancreatic survivorship. By looking at few individuals who survive pancreatic cancer for long periods of time, the team identified an initial set of high-quality neoantigens, or protein tags, on cancer cells that the immune system recognizes.  This project will continue the work to understand what makes a high-quality neoantigen and how the microbiome influences how the immune system recognizes it, with the goal of developing a method for creating vaccines to treat pancreatic cancers.  This research will have a significant impact on understanding neoantigen-T cell immunobiology and could improve the treatment prospects of pancreatic cancer patients.

Click here to see a full list of Dream Team members
Click here to see the press release announcement